Neil T. Thompson

2.6k total citations
47 papers, 1.6k citations indexed

About

Neil T. Thompson is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Neil T. Thompson has authored 47 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 11 papers in Oncology and 9 papers in Cell Biology. Recurrent topics in Neil T. Thompson's work include Chronic Lymphocytic Leukemia Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer-related Molecular Pathways (5 papers). Neil T. Thompson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer-related Molecular Pathways (5 papers). Neil T. Thompson collaborates with scholars based in United Kingdom, United States and Japan. Neil T. Thompson's co-authors include John F. Lyons, L.G. Garland, Robert W. Bonser, Michael C. Scrutton, Nicola G. Wallis, M. J. Jarvis, Marcus Richards, Michael Wadsworth, Matthew Squires and Michael J.O. Wakelam and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Neil T. Thompson

46 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil T. Thompson United Kingdom 24 956 328 307 192 192 47 1.6k
Albrecht Moritz United States 13 1.8k 1.9× 257 0.8× 413 1.3× 129 0.7× 147 0.8× 16 2.7k
Vardiella Meiner Israel 31 1.1k 1.2× 301 0.9× 210 0.7× 80 0.4× 103 0.5× 128 3.2k
Angela Alexander United States 22 1.4k 1.5× 367 1.1× 205 0.7× 172 0.9× 295 1.5× 55 2.6k
Bunzo Sato Japan 25 1.2k 1.3× 265 0.8× 314 1.0× 226 1.2× 144 0.8× 114 2.3k
Cristiana Stefan Canada 22 734 0.8× 211 0.6× 182 0.6× 240 1.3× 182 0.9× 48 1.9k
Jian Ma China 26 1.1k 1.1× 274 0.8× 175 0.6× 124 0.6× 143 0.7× 90 2.1k
Dan Zhou China 20 1.3k 1.4× 408 1.2× 110 0.4× 243 1.3× 341 1.8× 57 2.3k
Karen E. Sheppard Australia 27 1.5k 1.5× 693 2.1× 143 0.5× 376 2.0× 198 1.0× 68 2.7k
Fei Peng China 22 1.0k 1.1× 285 0.9× 291 0.9× 109 0.6× 88 0.5× 49 1.7k
Tohru Yamazaki Japan 18 702 0.7× 284 0.9× 158 0.5× 123 0.6× 213 1.1× 48 1.7k

Countries citing papers authored by Neil T. Thompson

Since Specialization
Citations

This map shows the geographic impact of Neil T. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil T. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil T. Thompson more than expected).

Fields of papers citing papers by Neil T. Thompson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil T. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil T. Thompson. The network helps show where Neil T. Thompson may publish in the future.

Co-authorship network of co-authors of Neil T. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Neil T. Thompson. A scholar is included among the top collaborators of Neil T. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil T. Thompson. Neil T. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Özer, Buğra, et al.. (2024). An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs. Nature Communications. 15(1). 5703–5703. 3 indexed citations
2.
Brownjohn, Philip W., et al.. (2024). Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease. Frontiers in Pharmacology. 15. 1397864–1397864. 2 indexed citations
3.
Chadwick, Wayne, Patricia Cogram, Daniel J. Mason, et al.. (2023). A novel combination treatment for fragile X syndrome predicted using computational methods. Brain Communications. 6(1). fcad353–fcad353. 2 indexed citations
4.
Ward, George A., Edward J. Lewis, Jong Sook Ahn, et al.. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics. 17(7). 1381–1391. 53 indexed citations
5.
Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2012). The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. Molecular Cancer Therapeutics. 11(8). 1799–1808. 49 indexed citations
6.
Graham, Brent, Jayne Curry, Tomoko Smyth, et al.. (2011). The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer. Cancer Science. 103(3). 522–527. 65 indexed citations
7.
Smyth, Tomoko, Thomas Van Looy, Jayne Curry, et al.. (2011). Abstract A217: The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models.. Molecular Cancer Therapeutics. 10(11_Supplement). A217–A217.
8.
Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations
9.
Dawson, Mark A., Jayne Curry, Philip Beer, et al.. (2010). AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. British Journal of Haematology. 150(1). 46–57. 41 indexed citations
10.
Squires, Matthew, Laurence Cooke, Victoria Lock, et al.. (2010). AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples. Molecular Cancer Therapeutics. 9(4). 920–928. 49 indexed citations
11.
Squires, Matthew, Ruth E. Feltell, Nicola G. Wallis, et al.. (2009). Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular Cancer Therapeutics. 8(2). 324–332. 134 indexed citations
12.
Tanaka, Ruriko, Matthew Squires, Shinya Kimura, et al.. (2008). Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.. Blood. 112(11). 1104–1104. 6 indexed citations
13.
Thompson, Neil T., John F. Lyons, Rachel McMenamin, et al.. (2007). Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.. Cancer Research. 67. 5641–5641. 2 indexed citations
14.
Lyons, John F., Steven J. Woodhead, Ruth E. Feltell, et al.. (2007). AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.. Molecular Cancer Therapeutics. 6. 2 indexed citations
15.
Hall, Simon R., et al.. (1999). CD4+CD45RA+ and CD4+CD45RO+ T cells differ in their TCR-associated signaling responses. European Journal of Immunology. 29(7). 2098–2106. 41 indexed citations
16.
Brown, Fraser D., Nicola Thompson, Khalid M. Saqib, et al.. (1998). Phospholipase D1 localises to secretory granules and lysosomes and is plasma-membrane translocated on cellular stimulation. Current Biology. 8(14). 835–838. 175 indexed citations
17.
Thompson, Neil T., Roger Randall, & L.G. Garland. (1995). Role of c-lyn in the functional effects of GM-CSF on human neutrophils. Biochemical Society Transactions. 23(2). 196S–196S. 7 indexed citations
18.
Thompson, Neil T., L.G. Garland, & Robert W. Bonser. (1993). Phospholipase D: Regulation and Functional Significance. Advances in pharmacology. 24. 199–238. 25 indexed citations
19.
Thompson, Neil T., Robert W. Bonser, & L.G. Garland. (1991). Receptor-coupled phospholipase D and its inhibition. Trends in Pharmacological Sciences. 12(11). 404–408. 93 indexed citations
20.
Thompson, Neil T., Robert W. Bonser, J.E. Tateson, et al.. (1991). A quantitative investigation into the dependence of Ca2+ mobilisation on changes in inositol 1,4,5‐trisphosphate levels in the stimulated neutrophil. British Journal of Pharmacology. 103(2). 1592–1596. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Albrecht Moritz Breakdown of academic impact, for papers by Vardiella Meiner Breakdown of academic impact, for papers by Angela Alexander Breakdown of academic impact, for papers by Bunzo Sato Breakdown of academic impact, for papers by Cristiana Stefan Breakdown of academic impact, for papers by Jian Ma Breakdown of academic impact, for papers by Dan Zhou Breakdown of academic impact, for papers by Karen E. Sheppard Breakdown of academic impact, for papers by Fei Peng Breakdown of academic impact, for papers by Tohru Yamazaki
Rankless by CCL
2026